Can use of hair products have an impact on breast cancer risk for women? That is a question explored by investigators from Rutgers Cancer Institute of New Jersey, Rutgers School of Public Health and other colleagues who examined use of hair dyes, hair relaxers and cholesterol-based hair products in African-American and Caucasian women.
The latest in childhood cancer statistics in New Jersey show significant declines in mortality rates for white, black and Hispanic children from 1979 to 2013. A Rutgers Cancer Institute of New Jersey expert says this improvement in survival can be attributed to treatment advances and participation in clinical trials.
While the risk of developing testicular cancer is low, every man should understand some basic facts about this disease. Rutgers Cancer Institute of New Jersey experts share more about the disease, which is the most common malignancy among men ages 15 to 35.
Improvements in chemotherapy and liver surgery have resulted in increased overall survival in patients with advanced stage colorectal cancer in recent decades. In order to better predict outcomes for these patients, researchers at Rutgers Cancer Institute of New Jersey conducted a retrospective analysis and found that stage IV colorectal cancer patients who survived at least two years have a better prognosis than originally thought.
While gemcitabine and brentuximab vedotin each have benefit when given individually in the treatment of Hodgkin lymphoma, Investigators from the Children’s Oncology Group including a Rutgers Cancer Institute of New Jersey physician-scientist examined the two therapies when combined in pediatric patients. They found the combination to be safe and to have a greater complete response rate than when the drugs are given individually.
An interim analysis of a phase I clinical trial examining a surgical procedure to remove the prostate and prostate cancer in men whose disease has spread (metastatic) shows the operation is safe and feasible in carefully selected patients.
A shorter course of radiation therapy given to breast cancer patients following mastectomy is safe and effective and cuts treatment time in half. That is according to data from a phase II clinical trial conducted by Rutgers Cancer Institute of New Jersey investigators and other colleagues who examined a hypofractionated regimen given over three weeks versus the traditional six week course of treatment.
Navigating a treatment path for cancer can be challenging for many patients, especially coordination of appointments between multiple practitioners. Combine that with a wealth of information about the disease which may not be easy to understand and there exists the potential for poor health outcomes. Nurses at Rutgers Cancer Institute of New Jersey explored both topics in order to further enhance the patient experience. Their findings are being presented as part of a poster session at the Oncology Nursing Society’s Annual Congress being held this week.
During this National Minority Health Month, there is a focus on bridging health equity in our communities including ensuring minority populations have access to high quality cancer screenings and treatments, adequate insurance coverage and other services. Health disparities researcher Jennifer Tsui, PhD of Rutgers Cancer Institute of New Jersey shares some insight.
Celebrating all types of libraries during National Library Week (April 9 - 16), Rutgers Cancer Institute of New Jersey is recognizing its own patient resources at its specialized library.
Research has shown that by themselves, the diabetes drug metformin and cholesterol-lowering drugs known as statins are associated with reduced cancer mortality, but little is known about the effect on pancreatic cancer mortality when these drugs are taken together. Investigators at Rutgers Cancer Institute of New Jersey examined SEER Medicare data to further explore this approach and found that exposure to statins for these patients was significantly associated with reduced overall mortality.
A ‘first in human’ clinical trial examining the small molecule drug ONC201 in cancer patients with advanced solid tumors shows that this investigational drug is well tolerated at the recommended phase II dose. That’s according to Rutgers Cancer Institute of New Jersey investigators whose research also showed early signs of clinical benefit in patients with advanced prostate and endometrial cancers.
Building on their previous research focusing on vaccination within a tumor (intratumoral) for the most common form of pancreatic cancer, investigators from Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School have shown that in a mouse model of early stage resected pancreatic cancer, intratumoral vaccination induces an anti-tumor response that results in a significant improvement in overall survival.
Highlighting progress and promise in cancer research, including advances made in colorectal cancer, representatives from Rutgers Cancer Institute of New Jersey, American Association of Cancer Research, and University Hospital recently met with Congressman Donald M. Payne, Jr., at Rutgers Cancer Institute of New Jersey at University Hospital in Newark.
Research by Rutgers University investigators – including a number from Rutgers Cancer Institute of New Jersey – has resulted in the development of small molecule inhibitors that block a protein involved in the development of some cancers. At focus are TAM receptors, which when overexpressed can make too many proteins leading to cancer development, drug resistance and overall poor patient survival.
During cancer treatment, the main focus is on the patient. However, a cancer diagnosis affects the entire family, including caregivers, whose needs often can be overlooked. During this Social Work Month, members of Rutgers Cancer Institute of New Jersey’s Social Work Department share some tips on how caregivers can keep their bodies and minds healthy – without breaking the bank or spending a lot of time – in order to provide the best care for the patient.
A drug given to reduce the side effects of strong post-surgery pain medications resulting in a reduced length of hospital stay for patients who have undergone major gastrointestinal or bladder cancer procedures is found to have similar benefit for some patients undergoing surgery for testicular cancer. An investigator at Rutgers Cancer Institute of New Jersey explored the impact of alvimopan in those patients who underwent RPLND.
A five-year, $1.8 million grant (R01CA203965) from the National Cancer Institute awarded to Rutgers Cancer Institute of New Jersey resident research member Wenwei Hu, PhD, will support research to further explore how chronic stress impacts cancer development.
As the nation's 69 National Cancer Institute-designated cancer centers come together in support of recently updated HPV vaccination recommendations, a Rutgers Cancer Institute of New Jersey gynecologic oncologist shares insight on how this vaccine can help prevent cervical cancer.
For more than a decade, there has been a focus on involving primary care providers in the follow-up care of cancer survivors. A new study by Rutgers University and Harvard Medical School finds that despite a number of proposed care models, there is limited information on the role that primary care providers play in this care.
A genomic analysis study by Rutgers Cancer Institute of New Jersey investigators and other colleagues has identified recurrent genomic alterations in a subset of breast cancer that are typically associated with a form of thyroid cancer and an intestinal birth defect known as Hirschsprung disease.
Aiming to further propel scientific discovery as well as augment and expand comprehensive cancer services for patients through collaborative efforts with Rutgers and RWJBarnabas Health, Steven K. Libutti, MD, FACS, has been named as the new Director of Rutgers Cancer Institute of New Jersey and will serve as Vice Chancellor for Cancer Programs for Rutgers Biomedical and Health Sciences at Rutgers University.
A Rutgers Cancer Institute of New Jersey researcher has received a $200,000 Grant from The V Foundation for Cancer Research to explore signaling in a cell pathway in triple-negative breast cancer.
A Rutgers Cancer Institute of New Jersey researcher has received a $596,250 award (W81XWH-16-1-0358) from the U.S. Department of Defense to study the role of chronic stress in breast cancer development. The focus of the work is to explore how chronic stress impacts breast cancer risk and to provide a foundation that can guide prevention strategies.
A $250,000 grant from the Breast Cancer Research Foundation awarded to a Rutgers Cancer Institute of New Jersey researcher will help further elucidate the inner workings of the p53 gene. The work will examine a drug compound that restores tumor suppressor function, with an aim of providing a foundation for the development of a new type of anti-cancer drug.
Rutgers Cancer Institute of New Jersey researchers in the Precision Medicine Program aim to validate a new genomic sequencing approach that may help identify a sub-set of triple-negative breast cancers. The work is supported by a grant from the Val Skinner Foundation.
A database study examining surgical removal of the prostate gland (radical prostatectomy) or a form of radiation therapy known as IMRT to treat prostate cancer that has spread to other parts of the body (metastatic) shows an association between each of these treatments and improved overall survival.
Researchers from Columbia University, Rutgers University, and other institutions have identified genomic alterations in pediatric relapsed ALL that cause both therapy resistance and improved clinical response to multi-agent chemotherapy treatment.
A new partnership between Rutgers Cancer Institute of New Jersey and University Hospital in Newark is resulting in the expansion of National Cancer Institute (NCI)-designated Comprehensive Cancer Center services to northern New Jersey.
Research from Rutgers Cancer Institute of New Jersey and other U.S. health and academic institutions shows a diet high in calcium and low in lactose may reduce the risk of ovarian cancer in African-American women. The work also found sun exposure in the summer months may reduce the risk of developing the disease in this population.
Thanks to a two-year, $70,000 commitment from Embrace Kids Foundation, the Comprehensive Sickle Cell Center housed at Rutgers Cancer Institute of New Jersey is expanding to include a Pediatric Sickle Cell and Hemoglobinopathies Nurse Navigator position.
Research from investigators at Rutgers Cancer Institute of New Jersey; University of California, Los Angeles; University of California, Santa Cruz and other institutions shows a computational approach examining abnormal “signaling” in clinical prostate cancer tissues that is responsible for their spread and resistance to treatment and can help identify patient subsets for targeted therapies.
Research from investigators at Rutgers Cancer Institute of New Jersey and Princeton University has identified a new approach to cancer therapy in cutting off a cancer cell’s ‘fuel supply’ by targeting a cellular survival mechanism known as autophagy.
Expanding the leadership of its five core research programs, Rutgers Cancer Institute of New Jersey has announced new roles for research members serving as co-program leaders, spanning across three divisions: basic science, clinical science, and population science.
Research from Rutgers Cancer Institute of New Jersey and Rutgers School of Public Health shows no significant decline in indoor tanning rates among children under age 17 following a ban on such use in New Jersey enacted in 2013. The authors say it’s a finding that underscores a need for continued surveillance of this population and ongoing monitoring of indoor tanning facilities.
Grants totaling $450,000, have been awarded to a number of investigators at Rutgers Cancer Institute of New Jersey. The Pre- and Post-Doctoral Fellowship Awards from the New Jersey Commission on Cancer Research will help support various research projects relating to cancer biology and population studies.
Social strains and lack of social competence are common in children recovering from malignant brain tumors. A Rutgers Cancer Institute of New Jersey behavioral scientist and colleagues from across the U.S. and Canada, examined a peer-mediated intervention at the survivor’s school and found it was feasible to carry out in the public school setting and was acceptable to the survivor’s family.
Researchers from Rutgers Cancer Institute of New Jersey and Massachusetts General Hospital Cancer Center have been awarded a $2.2 million grant to further explore and improve upon available cancer therapies that aim to block specific pathways that promote tumor growth.
A number of physicians at Rutgers Cancer Institute of New Jersey have been named as a ‘Top Doctor for Cancer Care’ by 'Inside Jersey' magazine.
An effort by Rutgers Cancer Institute of New Jersey to educate pediatric cancer survivors about late effects from cancer treatment is receiving a boost from The National Children’s Cancer Society (NCCS) in the form of a ‘Beyond the Cure’ educational survivorship conference grant.
An investigational immunotherapy drug being tested in the treatment of a rare form of skin cancer known as Merkel cell carcinoma has been found to be well tolerated with a clinical benefit seen in up to 42 percent of patients who failed prior treatment and were observed for at least six months.
As the chance of being diagnosed with thyroid cancer has risen in recent years, an investigator at Rutgers Cancer Institute of New Jersey and colleagues are exploring the impact of the immunotherapy drug pembrolizumab on advanced disease. Updated results of their research will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
Is a couples’ support group or an enhanced couples’ group therapy intervention with skill instruction more effective for helping women diagnosed with early stage breast cancer? Research from a Rutgers Cancer Institute of New Jersey investigator and others shows each has its own benefits depending on the patient’s stress level.
Aiming to better understand gender differences in lung cancer, a Rutgers Cancer Institute of New Jersey researcher is exploring whether radiation exposure from interventional cardiovascular procedures leads to increased risk of lung cancer in women as compared to men. The work is supported by an inaugural $400,000 LUNG FORCE Research Innovation Project award.
Director of the Center for Integrative Proteomics Research at Rutgers University, Stephen K. Burley, MD, DPhil, has been named as co-leader of the Cancer Pharmacology Research Program at Rutgers Cancer Institute.
Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital Hamilton (RWJ Hamilton) have announced the appointment of breast surgeon Firas Eladoumikdachi, MD, FACS, as Program Director for the Rutgers Cancer Institute of New Jersey at Hamilton – the cancer center at RWJ Hamilton. He will be responsible for clinical leadership of the oncology service line at RWJ Hamilton including medical, surgical and radiation oncology.
Caring for cancer patients may be the first thing that comes to mind when thinking about the work of an oncology nurse, but the role involves so much more.To recognize the scope of their work, which includes research and peer mentoring, Rutgers Cancer Institute nurses were celebrated this week with Oncology Nursing Excellence Awards.
The topic of sexual dysfunction may be a difficult one to discuss between healthcare providers and cancer patients. The nursing and social work teams at Rutgers Cancer Institute of New Jersey explored this issue in order to improve the conversation and ensure quality oncology care. Nurses also examined how to ensure the safety of alternate route chemotherapy administration. The work is being presented at the Oncology Nursing Society’s Annual Congress meeting this week in San Antonio.
Research from Rutgers Cancer Institute of New Jersey examining gynecologic cancers that poorly respond to therapy shows genomic profiling can help identify alternate and targeted treatments.
A Rutgers Cancer Institute of New Jersey researcher has been awarded a $1.8-million grant from the National Cancer Institute to build upon research examining a drug compound that restores tumor suppressor function in the most commonly mutated gene in human cancer – the p53 gene.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right